Graf, S.* ; Engelmann, L.* ; Jeleff Wölfler, O.* ; Albrecht, I.* ; Schloderer, M.* ; Kramer, A.* ; Klankermayer, L.* ; Gebhardt, F.* ; Chaker, A.M.* ; Spinner, C.D.* ; Schwab, R.* ; Wollenberg, B.* ; Protzer, U. ; Hoffmann, D.
     
 
    
        
Reopening the Bavarian state opera safely: Hygiene strategies and incidence of COVID-19 in artistic staff during theater season 2020/2021.
    
    
        
    
    
        
        J. Voice 38, 798.e7-798.e20 (2021)
    
    
    
		
		
			
				Due to the drastically rising coronavirus disease (COVID-19) incidence since March 2020, social life was shut down across the globe, and most opera houses were closed. As a result, there are limited data on SARS-CoV-2 infections among artists. The Bavarian State Opera has been reopened in September 2020. This study aimed to identify the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among employees in the Bavarian State Opera. In addition, the various hygiene strategies for the work groups within the institution are described. During the study period from September 1, 2020 to July 31, 2021, 10,061 nasopharyngeal swabs were obtained from 1,460 artistic staff members in a rolling system. During the entire study period, 61 individuals tested positive for SARS-CoV-2. None of the patients had a severe disease course. Compared to the seven-day-incidence per 100,000 German inhabitants, the estimated corresponding incidence among employees was lower at 37 weeks and higher or equal at 9 weeks. Among the infected individuals, 58.3% were symptomatic, 23.3% were presymptomatic, and 18.3% were asymptomatic. Forty-five percent of employees reported that they had been infected in their private environment, 41.7% suspected that their colleagues were the main contact, and 13.3% were unsure about the origin of their infection. Twenty-four diseased employees were ballet dancers, eight from the orchestra, seven from the administration, seven from the choir singers, six from the costume department, 10 from technical support, and one guest solo singer. In the 2020/2021 theater season, increased SARS-CoV-2 infections and large disease outbreaks were avoided at the Bavarian State Opera. Hygiene strategies, that existed since the beginning, was specifically designed for various work areas in the opera. Regular, mandatory PCR testing and follow-up of positive cases with the issuance of quarantine were performed. Using this disease management approach, artistic work at and reopening of the Bavarian State Opera was feasible with a well-controlled risk.
			
			
				
			
		 
		
			
				
					
					Impact Factor
					Scopus SNIP
					Web of Science
Times Cited
					Scopus
Cited By
					
					Altmetric
					
				 
				
			 
		 
		
     
    
        Publikationstyp
        Artikel: Journalartikel
    
 
    
        Dokumenttyp
        Wissenschaftlicher Artikel
    
 
    
        Typ der Hochschulschrift
        
    
 
    
        Herausgeber
        
    
    
        Schlagwörter
        Asymptomatic Covid-19 Infection ; Ballet Dancer ; Incidence Of Sars-cov-2 ; Musician ; Singer
    
 
    
        Keywords plus
        
    
 
    
    
        Sprache
        englisch
    
 
    
        Veröffentlichungsjahr
        2021
    
 
    
        Prepublished im Jahr 
        0
    
 
    
        HGF-Berichtsjahr
        2021
    
 
    
    
        ISSN (print) / ISBN
        0892-1997
    
 
    
        e-ISSN
        1873-4588
    
 
    
        ISBN
        
    
 
    
        Bandtitel
        
    
 
    
        Konferenztitel
        
    
 
	
        Konferzenzdatum
        
    
     
	
        Konferenzort
        
    
 
	
        Konferenzband
        
    
 
     
		
    
        Quellenangaben
        
	    Band: 38,  
	    Heft: 3,  
	    Seiten: 798.e7-798.e20 
	    Artikelnummer: ,  
	    Supplement: ,  
	
    
 
  
        
            Reihe
            
        
 
        
            Verlag
            Mosby
        
 
        
            Verlagsort
            360 Park Avenue South, New York, Ny 10010-1710 Usa
        
 
	
        
            Tag d. mündl. Prüfung
            0000-00-00
        
 
        
            Betreuer
            
        
 
        
            Gutachter
            
        
 
        
            Prüfer
            
        
 
        
            Topic
            
        
 
	
        
            Hochschule
            
        
 
        
            Hochschulort
            
        
 
        
            Fakultät
            
        
 
    
        
            Veröffentlichungsdatum
            0000-00-00
        
 
         
        
            Anmeldedatum
            0000-00-00
        
 
        
            Anmelder/Inhaber
            
        
 
        
            weitere Inhaber
            
        
 
        
            Anmeldeland
            
        
 
        
            Priorität
            
        
 
    
        Begutachtungsstatus
        Peer reviewed
    
 
     
    
        POF Topic(s)
        30203 - Molecular Targets and Therapies
    
 
    
        Forschungsfeld(er)
        Immune Response and Infection
    
 
    
        PSP-Element(e)
        G-502700-003
    
 
    
        Förderungen
        Repha Pharma
Janssen-Cilag
Eli Lilly
MSD
Cepheid
GSK
ALK-Abello
Allergopharma, ASIT Biotech
German Federal Ministry of Education and Research
Roche
Sano fi Genzyme
AbbVie
Astra Zeneca
BMBF via the Network University Medicine (NUM)
    
 
    
        Copyright
        
    
 	
    
    
    
    
    
        Erfassungsdatum
        2022-02-02